FDA Approves Injectable Drug To Treat Plaque Psoriasis.
The Wall Street Journal (3/22, Beilfuss, Subscription Publication) reports that the Food and Drug Administration approved Eli Lilly & Co.’s Taltz (ixekizumab), an injectable drug to treat adults with moderate-to-severe plaque psoriasis. According to Eli Lilly, 41% of patients treated with Taltz had clear skin by week 12.
The American Academy of Dermatology points out about 7.5 million people suffer from psoriasis, with approximately 80-90% having plaque psoriasis. Also covering the story are Reuters (3/22, Berkrot), the Indianapolis Business Journal (3/22, Russell), MedPage Today (3/22, Peck), and Medscape (3/22, Brooks).